FI930608A0 - Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol - Google Patents

Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol

Info

Publication number
FI930608A0
FI930608A0 FI930608A FI930608A FI930608A0 FI 930608 A0 FI930608 A0 FI 930608A0 FI 930608 A FI930608 A FI 930608A FI 930608 A FI930608 A FI 930608A FI 930608 A0 FI930608 A0 FI 930608A0
Authority
FI
Finland
Prior art keywords
methylthiazole
hydroxyethyl
chloro
pharmaceutical formulation
solvate
Prior art date
Application number
FI930608A
Other languages
English (en)
Finnish (fi)
Other versions
FI930608A7 (fi
FI930608L (fi
Inventor
Bernard Robin Boar
Alan John Cross
Alfred Richard Green
Curt-Eric Hagberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of FI930608A7 publication Critical patent/FI930608A7/fi
Publication of FI930608L publication Critical patent/FI930608L/fi
Publication of FI930608A0 publication Critical patent/FI930608A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FI930608A 1990-08-15 1991-08-07 Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol FI930608A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002659A SE9002659D0 (sv) 1990-08-15 1990-08-15 New pharmaceutical formulations
PCT/SE1991/000522 WO1992003134A1 (en) 1990-08-15 1991-08-07 New pharmaceutical formulations of 5-(2-chloro-1-hydroxyethyl)-4-methylthiazole

Publications (3)

Publication Number Publication Date
FI930608A7 FI930608A7 (fi) 1993-02-11
FI930608L FI930608L (fi) 1993-02-11
FI930608A0 true FI930608A0 (fi) 1993-02-11

Family

ID=20380161

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930608A FI930608A0 (fi) 1990-08-15 1991-08-07 Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol

Country Status (26)

Country Link
US (1) US5385921A (cs)
EP (1) EP0619734B1 (cs)
JP (1) JP3094077B2 (cs)
AT (1) ATE164066T1 (cs)
AU (1) AU657490B2 (cs)
BG (1) BG97446A (cs)
CA (1) CA2088775A1 (cs)
CZ (1) CZ279586B6 (cs)
DE (1) DE69129126T2 (cs)
DK (1) DK0619734T3 (cs)
ES (1) ES2114891T3 (cs)
FI (1) FI930608A0 (cs)
HU (1) HUT65821A (cs)
IE (1) IE912818A1 (cs)
IL (1) IL99169A (cs)
IS (1) IS3743A7 (cs)
LT (1) LT3978B (cs)
LV (1) LV10921B (cs)
NO (1) NO303447B1 (cs)
NZ (1) NZ239329A (cs)
PT (1) PT98688B (cs)
RO (1) RO112994B1 (cs)
RU (1) RU2093155C1 (cs)
SE (1) SE9002659D0 (cs)
SK (1) SK8793A3 (cs)
WO (1) WO1992003134A1 (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901658D0 (sv) * 1999-05-06 1999-05-06 Astra Ab New formulation
SE9904177D0 (sv) * 1999-11-18 1999-11-18 Astra Ab Novel compounds
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
CN103772313B (zh) * 2014-01-02 2015-10-14 郑桂富 一种4-甲基-5-(2-羟乙基)噻唑的合成方法
CN112262814A (zh) * 2020-10-26 2021-01-26 宜宾学院 油樟叶渣发酵床养鸡方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825966A1 (de) * 1978-06-14 1980-01-03 Basf Ag Saures galvanisches nickelbad, das sulfobetaine als glanz- und einebnungsmittel enthaelt
GB8600783D0 (en) * 1986-01-14 1986-02-19 Merck Sharp & Dohme N-methyl-d-aspartate receptor antagonists

Also Published As

Publication number Publication date
WO1992003134A1 (en) 1992-03-05
RO112994B1 (ro) 1998-03-30
EP0619734A1 (en) 1994-10-19
LT3978B (en) 1996-06-25
RU2093155C1 (ru) 1997-10-20
FI930608A7 (fi) 1993-02-11
DK0619734T3 (da) 1998-10-05
IL99169A (en) 1995-10-31
IS3743A7 (is) 1992-02-16
NO303447B1 (no) 1998-07-13
NO930452D0 (no) 1993-02-09
ES2114891T3 (es) 1998-06-16
PT98688A (pt) 1992-07-31
SK8793A3 (en) 1993-07-07
JP3094077B2 (ja) 2000-10-03
DE69129126D1 (de) 1998-04-23
US5385921A (en) 1995-01-31
AU8409291A (en) 1992-03-17
FI930608L (fi) 1993-02-11
IL99169A0 (en) 1992-07-15
ATE164066T1 (de) 1998-04-15
JPH06500097A (ja) 1994-01-06
BG97446A (bg) 1994-03-24
SE9002659D0 (sv) 1990-08-15
EP0619734B1 (en) 1998-03-18
IE912818A1 (en) 1992-02-26
LV10921A (lv) 1995-12-20
LTIP1714A (en) 1995-09-25
CA2088775A1 (en) 1992-02-16
AU657490B2 (en) 1995-03-16
CZ16693A3 (en) 1994-02-16
LV10921B (en) 1996-08-20
NO930452L (no) 1993-02-09
HU9300388D0 (en) 1993-04-28
NZ239329A (en) 1994-11-25
PT98688B (pt) 1999-01-29
DE69129126T2 (de) 1998-07-23
HUT65821A (en) 1994-07-28
CZ279586B6 (cs) 1995-05-17

Similar Documents

Publication Publication Date Title
NO914667L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylderivater
FI925342L (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
NO156785C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklobutan-derivater.
FI932553L (fi) Nya farmaceutiska formulationer innehaollande ett farmakologiskt aktivtjoniserbart aemne samt process foer framstaellning daerav
NO910935D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive c-bundne pyrazol-derivater.
NO171853C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 7beta-(2-(tiazol-4-yl)-2-alkoksyiminoacetamido)-3-((1-pyrazolio)metyl)-3-cefem-4-karboksylat-forbindelser
NO903941D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-derivater.
NO172575C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzocykloalkanderivater
NO902710D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive r(-) 3-kinuklidinol-derivater.
NO167734C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte aminderivater.
FI930608A0 (fi) Nya farmaceutiska formulationer av 5-(2-klor-1-hydroxietyl)-4-metyltiazol
TR27833A (tr) Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.
NO159090C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.
ZA911452B (en) New use of 5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene-bis(dimethylcarbanate)
RU93004984A (ru) Фармацевтическая композиция на основе 5(2-хлор-1-гидроксиэтил)-4-метилтиазола, применение 5-(2-хлор-1-гидроксиэтил)-4-метил-тиазола для лечения, способ лечения, соли 5-(2-хлор-1-гидроксиэтил)-4-метилтиазола
IT1095388B (it) Composizione farmaceutica per la somministrazione di pancreatina
IT9021021A0 (it) Composizioni farmaceutiche per la somministrazione orale di irudina
NO178302C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte 3-tia- henholdsvis 3-oksa-alkylflavoner, samt mellomprodukter for fremgangsmåten
NO167974C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminopropanolderivater av 3-(2-hydroksyfenyl)-1-propanonforbindelser.
NO173140C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tieno-triazolo-diazepin-derivater
NO171451C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenetanolamin-derivater
IT9048110A0 (it) Composizioni farmaceutiche per la somministrazione rettale di calcitonina
MX9203359A (es) Nuevas composiciones farmaceuticas de insulina.
IT1100372B (it) Associazione di antibiotici caratterizzata da diminuita tossicita',e composizioni farmaceutiche relative
NO160443C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ASTRA AKTIEBOLAG